Evidence map›Paper›PMID 26802323›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2016

Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.

Eric J Chow, Lynnette Anderson, K Scott Baker, Smita Bhatia, Gregory M T Guilcher, Jennifer T Huang, Wendy Pelletier, Joanna L Perkins, Linda S Rivard, Tal Schechter and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 10 pooled it
45.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 10 syntheses or guidelines pooled it, 198 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Trial
  12. Vascular Structure and Function in Cancer Survivors after Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 2 countries.

Eric J ChowClinical Research and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, University of Washington, Seattle, Washington. Electronic address: ericchow@u.washington.edu.
Lynnette AndersonDepartment of Pediatric Hematology, Oncology, and Bone Marrow Transplant, Medical College of Wisconsin, Milwaukee, Wisconsin.
K Scott BakerClinical Research and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, University of Washington, Seattle, Washington.
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Gregory M T GuilcherDepartments of Oncology and Paediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
Jennifer T HuangDepartment of Dermatology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Wendy PelletierDepartments of Oncology and Paediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
Joanna L PerkinsDepartment of Cancer and Blood Disorders, Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota.
Linda S RivardDepartment of Pediatric Hematology Oncology, Advocate Children's Hospital, Oak Lawn, Illinois.
Tal SchechterDepartment of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
Ami J ShahDivision of Stem Cell Transplant and Regenerative Medicine, Lucile Packard Children's Hospital, Stanford University, Stanford, California.
Karla D WilsonDepartment of Population Sciences, City of Hope National Medical Center, Duarte, California.
Kenneth WongDepartment of Radiation Oncology, Children's Hospital of Los Angeles, University of Southern California, Los Angeles, California.
Satkiran S GrewalDepartment of Pediatrics, Baystate Children's Hospital, Tufts University School of Medicine, Springfield, Massachusetts.
Saro H ArmenianDepartment of Population Sciences, City of Hope National Medical Center, Duarte, California.
Lillian R MeachamDepartment of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
Daniel A MulrooneyDepartment of Oncology, St. Jude Children's Research Hospital, University of Tennessee Health Science Center, Memphis, Tennessee.
Sharon M CastellinoDepartment of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
City Of Hope National Medical Center · USEmory University · USSeattle Children's Hospital · USUniversity of Calgary · CAAdvocate Children's Hospital · USBoston Children's Hospital · USChildren’s Minnesota - St. Paul Hospital · USHospital for Sick Children · CALucile Packard Children's Hospital · USMedical College of Wisconsin · USSt. Jude Children's Research Hospital · USTufts University · USUniversity of Alabama at Birmingham · USUniversity of Southern California · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5M
Determinants of late cardiovascular morbidity among survivors of hematopoietic ceK07CA151775 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHOW, ERIC JESSEN · 2011 to 2015
$755k
NCI NIH HHS K07 CA151775NCI NIH HHS U10 CA180886NCI NIH HHS UG1 CA189955
6 · The paper itself

Abstract

Hematopoietic cell transplantation (HCT) is an important curative treatment for children with high-risk hematologic malignancies, solid tumors, and, increasingly, nonmalignant diseases. Given improvements in care, there are a growing number of long-term survivors of pediatric HCT. Compared with childhood cancer survivors who did not undergo transplantation, HCT survivors have a substantially increased burden of serious chronic conditions and impairments involving virtually every organ system and overall quality of life. This likely reflects the joint contributions of pretransplantation treatment exposures and organ dysfunction, the transplantation conditioning regimen, and any post-transplantation graft-versus-host disease (GVHD). In response, the Children's Oncology Group (COG) has created long-term follow-up guidelines (www.survivorshipguidelines.org) for survivors of childhood, adolescent, and young adult cancer, including those who were treated with HCT. Guideline task forces, consisting of HCT specialists, other pediatric oncologists, radiation oncologists, organ-specific subspecialists, nurses, social workers, other health care professionals, and patient advocates systematically reviewed the literature with regards to late effects after childhood cancer and HCT since 2002, with the most recent review completed in 2013. For the most recent review cycle, over 800 articles from the medical literature relevant to childhood cancer and HCT survivorship were reviewed, including 586 original research articles. Provided herein is an organ system-based overview that emphasizes the most relevant COG recommendations (with accompanying evidence grade) for the long-term follow-up care of childhood HCT survivors (regardless of current age) based on a rigorous review of the available evidence. These recommendations cover both autologous and allogeneic HCT survivors, those who underwent transplantation for nonmalignant diseases, and those with a history of chronic GVHD.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationSurvivorsAdolescentAdultAdvisory CommitteesAllograftsChildChild, PreschoolChronic DiseaseFemaleHumansMaleNeoplasmsPractice Guidelines as TopicRisk FactorsChildhoodGuidelineHematopoietic cell transplantationLate effectsSurveillanceSurvivor

Identifiers

PMID26802323
PMCPMC4826622
OpenAlexW2252030468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.